Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for May, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- What is the Stock Market's Achilles Heel?
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Oil & Gas Industry Stock Outlook - May 2013
- Uncharted Territory
- 4 Ways to Short Oil with ETFs
- Options Strategies & the Zacks Rank
- This Week's Growth & Income Stocks
- AWS 5/17: The Fed: The Only Game in Town
- PFP 5/17: The ONLY Investment Story
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/17/2013
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
In a bid to strengthen its multiple sclerosis and cancer franchises, Merck KGaA ( MKGAF ) entered into a couple of agreements with Japanese pharma company, Ono Pharmaceutical Co. Ltd.
According to the first agreement, Merck KGaA will have worldwide (excluding Japan, Korea and Taiwan) license rights for the development and commercialization of ONO-4641, which is currently in mid-stage development for the treatment of multiple sclerosis. For this agreement, Ono Pharma will receive 1.5 billion Japanese Yen (about €14 million) as an upfront payment and is also eligible to receive additional payments on the achievement of certain development, regulatory and commercial milestones for ONO-4641.
The second license agreement provides Ono Pharma with the Japanese co-development and co-marketing rights to Stimuvax. Outside Japan, Stimuvax is currently being studied in late-stage trials as a treatment for patients suffering from non-small cell lung cancer. Within Japan, a mid-stage trial for the said indication is currently ongoing for the candidate. Merck KGaA will receive an upfront payment of €5 million as a part of this agreement. Merck KGaA obtained exclusive worldwide licensing rights for Stimuvax from Oncothyreon Inc. ( ONTY - Snapshot Report ) .
We note that the company has been busy signing deals and acquiring companies lately. Last month, Merck KGaA announced the acquisition of exclusive worldwide development and commercialization rights to multiple sclerosis (MS) candidate PI-2301. The candidate was being developed by Peptimmune Inc.%2
Read the full on MKGAF
Read the full Snapshot Report on ONTY